Site icon OncologyTube

Marlise R. Luskin, MD, MSCE – Venetoclax and Navitoclax

Marlise R. Luskin, MD, MSCE is a physician in Dana-Farber’s Adult Leukemia program.

Meet Marlise Luskin, MD, MSCE, an esteemed Assistant Professor of Medicine and Senior Physician at Dana-Farber Cancer Institute in Boston, Massachusetts. With a focus on acute lymphoblastic leukemia, Marlise sheds light on the pivotal role of venetoclax in its treatment. Through insightful analysis of preclinical evidence, she explores the drug’s potential sensitivity against the disease, particularly when paired with diverse chemotherapy agents.

REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS
AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/
AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/
MPN-MDS EU – registration open – https://mpn-mdseu2023.md-education.com/register/
Register – AML-ALL US Focus Meeting 2023
aml-allus2023.md-education.com

Her thorough review encompasses trials that blend venetoclax and Navitoclax, the former a BCL-2 inhibitor and the latter a dual BCL-2/BCL-XL inhibitor. Marlise delves into the trials’ strategic integration of these drugs in both relapse and front-line scenarios. At the heart of her presentation lies the excitement of collaborative discussions and engaging Q&A sessions, enhancing the overall experience of the conference.

Exit mobile version